Notice We create sustainable value for patients, employees, shareholders and society

HNSCC ASCO 2023 poster presentation accepted

Apr 10, 2023Genexine

Notice for Shareholders

Genexine, Inc. is excited to announce that a poster presentation at ASCO 2023 has been accepted for the HNSCC(Head and Neck Cancer) triple combo study of GX-I7, 188E and pembrolizumab

Here are a few key facts for your information.


  • The trial is an ongoing Ph2 IIT(Investigator Initiated Trial) by prof. Hye-Ryun Kim of Severance Hospital, Yonsei univ. 
  • Abstract will be available on ASCO website from May 25th
  • ASCO Annual Meeting will be held in Chicago, IL. from June 2nd to 4th


The company will share the abstract with the public once it is disclosed on ASCO website. 

Thank you. 


Genexine IR.